Salud financiera de hoja de balance de Zomedica

Salud financiera controles de criterios 6/6

Zomedica tiene un patrimonio de los accionistas total de $202.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $214.1M y $11.3M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$76.88m
Patrimonio	US$202.84m
Total pasivo	US$11.27m
Activos totales	US$214.12m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($87.3M) de ZOM superan a sus pasivos a corto plazo ($8.1M).

Pasivo a largo plazo: Los activos a corto plazo de ZOM ($87.3M) superan a sus pasivos a largo plazo ($3.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ZOM está libre de deudas.

Reducción de la deuda: ZOM no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ZOM tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: ZOM dispone de suficiente cash runway para 1.9 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 16% cada año.

Salud financiera de hoja de balance de Zomedica

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Zomedica Receives Non-Compliance Notice from NYSE American

Recent updates

Senior Vice President of Sales recently bought US$60k worth of stock

Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform

Third quarter 2024 earnings released: US$0.007 loss per share (vs US$0.001 loss in 3Q 2023)

Zomedica Corp. Launches Ear Cytology Quick Scan Protocol for TRUVIEW Digital Microscope & Telepathology Platform

Zomedica Corp. to Report Q3, 2024 Results on Nov 07, 2024

Zomedica's Assisi Loop Product Line Designated as Fear Free(TM) Preferred Product

Zomedica Corp. Introduces Enhanced Audio Features for the Vetguardian Zero-Touch Vital Signs Remote Monitoring System

Second quarter 2024 earnings released: US$0.024 loss per share (vs US$0.005 loss in 2Q 2023)

Zomedica Corp. Reiterates Financial Guidance for Full Year 2024

Zomedica Corp. Expands Truforma Addressable Market with Launch of Equine Cortisol Assay for the Platform

Senior Vice President of Sales recently bought US$105k worth of stock

Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform

Zomedica Corp. Provides Revenue Guidance for Full Year 2024

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.009 loss per share (vs US$0.007 loss in 1Q 2023)

Zomedica Corp. to Report Q1, 2024 Results on May 09, 2024

Zomedica Corp., Annual General Meeting, Jun 06, 2024

Zomedica Corp. Provides Revenue Guidance for Full Year 2024

Full year 2023 earnings released: US$0.035 loss per share (vs US$0.017 loss in FY 2022)

Zomedica Corp. to Report Q4, 2023 Results on Apr 01, 2024

Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay (CLIA) Platform

New minor risk - Share price stability

Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024

Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease

Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.005 loss in 3Q 2022)

Zomedica Corp. to Report Q3, 2023 Results on Nov 13, 2023

Zomedica Corp. (NYSEAM:ZOM) acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc.

Zomedica Corp. Launches its Newest Assay - Endogenous ACTH

Zomedica Receives Non-Compliance Notice from NYSE American

Second quarter 2023 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2022)

High number of new directors

New major risk - Revenue and earnings growth

Zomedica Corp. Launches Revolutionary TRUVIEW(TM) Digital Microscope with Advanced Optics, Automated Slide Preparation, and Telepathology Services

First quarter 2023 earnings released: US$0.007 loss per share (vs US$0.004 loss in 1Q 2022)

Full year 2022 earnings released: US$0.017 loss per share (vs US$0.053 loss in FY 2021)

Zomedica Corp. to Report Q4, 2022 Results on Mar 15, 2023

Third quarter 2022 earnings released: US$0.005 loss per share (vs US$0.006 loss in 3Q 2021)

Zomedica Corp. to Report Q3, 2022 Results on Nov 14, 2022

Zomedica Corp. Announces Launch of Free T4 Assay for Truforma(R) Diagnostic Platform

Zomedica Corp. Appoints Pamela Nichols to Board of Directors and Audit and Governance Committees

Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.005 loss in 2Q 2021)

Zomedica Corp. (NYSEAM:ZOM) acquired Substantially All the Assets of Assisi Animal Health, LLC.

Zomedica Corp. Announces Management Changes

First quarter 2022 earnings released: US$0.004 loss per share (vs US$0.041 loss in 1Q 2021)

Zomedica Corp. Signs TRUFORMA Distribution Agreement with Miller Veterinary Supply

Zomedica Corp. Appoints Robert Cohen as Chief Executive Officer

Zomedica Corp. Appoints Ann Marie Cotter as Chief Financial Officer

Zomedica Pharmaceuticals Corp. Approves Board Appointments

Zomedica Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $29.9975 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera